Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 7045 to 7045 of 7045 entries
Sorted by: Best Match Show Resources per page
Comparisons of survival outcomes between bevacizumab and olaparib in .

Journal of gynecologic oncology

Kim SI, Lee JW, Kim K, Lee M, Yoo J, Choi MC, Hwangbo S, Kwak YH, Lee JM, Shin SJ, Shim SH, Kim MK.
PMID: 34431258
J Gynecol Oncol. 2021 Nov;32(6):e90. doi: 10.3802/jgo.2021.32.e90. Epub 2021 Aug 05.

OBJECTIVE: To compare survival outcomes between bevacizumab (BEV) and olaparib (OLA) maintenance therapy in METHODS: From 10 institutions, we identified HGSOC patients with germline and/or somatic RESULTS: Overall, OLA users showed significantly better progression-free survival (PFS) than BEV users...

Cite
Kim SI, Lee JW, Kim K, et al. Comparisons of survival outcomes between bevacizumab and olaparib in . J Gynecol Oncol. 2021;32(6):e90doi: 10.3802/jgo.2021.32.e90.
Kim, S. I., Lee, J. W., Kim, K., Lee, M., Yoo, J., Choi, M. C., Hwangbo, S., Kwak, Y. H., Lee, J. M., Shin, S. J., Shim, S. H., & Kim, M. K. (2021). Comparisons of survival outcomes between bevacizumab and olaparib in . Journal of gynecologic oncology, 32(6), e90. https://doi.org/10.3802/jgo.2021.32.e90
Kim, Se Ik, et al. "Comparisons of survival outcomes between bevacizumab and olaparib in ." Journal of gynecologic oncology vol. 32,6 (2021): e90. doi: https://doi.org/10.3802/jgo.2021.32.e90
Kim SI, Lee JW, Kim K, Lee M, Yoo J, Choi MC, Hwangbo S, Kwak YH, Lee JM, Shin SJ, Shim SH, Kim MK. Comparisons of survival outcomes between bevacizumab and olaparib in . J Gynecol Oncol. 2021 Nov;32(6):e90. doi: 10.3802/jgo.2021.32.e90. Epub 2021 Aug 05. PMID: 34431258; PMCID: PMC8550925.
Copy Download .nbib Format: NLM
Showing 7045 to 7045 of 7045 entries